Business
New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer
In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPCReal‑world evidence showed Pluvicto achieved longer PFS when initiated after one ARPI instead of multiple ARPIs A separate analysis of treatment patterns in metastatic hormone-sensitive prostate cancer suggest significant opportunity for increased guideline adherence Basel, February 24, 2026 – Novartis today announced multiple US real-world studies delivering new insights across metastatic
About this update from Novartis Ag
[{"type":"image","alt":"Novartis Pharma AG","displaySize":"","headline":null,"caption":"Novartis Pharma AG","className":"","disableSlideshowImg":false,"size":{"original":{"width":287,"height":55,"url":"https://media.zenfs.com/en/globenewswire.com/838a2f0cbe482ce95bb28a161721a308"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jVHT.jc1r.9_PBg7JQVa4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/838a2f0cbe482ce95bb28a161721a308","width":287,"height":55}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPC","length":107,"tagName":"p"}]},{"val":[{"type":"text","content":"Real‑world evidence showed Pluvicto achieved longer PFS when initiated after one ARPI instead of multiple ARPIs ","length":111,"tagName":"p"}]},{"val":[{"type":"text","content":"A separate analysis of treatment patterns in metastatic hormone-sensitive prostate cancer suggest significant opportunity for increased guideline adherence","length":155,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":373,"olType":false},{"type":"text","content":"Basel, February 24, 2026 – Novartis today announced multiple US real-world studies delivering new insights across metastatic prostate cancer care. The analyses utilize data from Novartis’ PRECISION platform to evaluate Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan) effectiveness and sequencing as well as real‑world treatment patterns in earlier metastatic disease. These studies will be presented at the ASCO Genitourinary Cancers Symposium on February 26, 2026.","length":468,"tagName":"p"},{"type":"text","content":"Pluvicto shows real-world effectiveness in taxane-naïve mCRPC patientsReal-world use of Pluvicto resulted in a median progression-free survival (PFS) of 13.5 months (95% CI: 11.7 – 14.7 months) in men with metastatic castration-resistant prostate cancer (mCRPC) who had been treated with ≥1 androgen receptor pathway inhibitor (ARPI) and were taxane-naïve. Results showed chemo-naïve patients treated with Pluvicto after only 1 ARPI had longer median PFS (15.8 months; 95% CI: 11.7 - 18.6 months) than those who received Pluvicto after multiple ARPIs (12.7 months; 95% CI: 10.7 - 14.0 months)1.","length":595,"tagName":"p"},{"type":"text","content":"“This ana...